Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX─201 to treat ...
Pacira BioSciences, Inc., the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, announced the first patient has been dosed in the phase 2 ASCEND study of PCRX-201 (enekinragene …